Tomohiro Sasaki
Tomohiro Sasaki has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Koushi Higashi
Office of Clinical Pharmacology, Department of Biometrics, Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., 3-2-27 Otemachi, Chuo-ku, Osaka, Japan
3 shared publications - Daisuke Sekine
Medical Affairs Otsuka Pharmaceutical Co., Ltd. Tokyo Japan
2 shared publications - Kazuo Aoki
Medical Affairs, Otsuka Pharmaceutical Co. Ltd., Tokyo
2 shared publications - Yosuke Kawai
Office of Clinical Pharmacology, Department of Biometrics, Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., 3-2-27 Otemachi, Chuo-ku, Osaka, Japan
2 shared publications Atsushi Kitamura
Clinical Pharmacology, Sumitomo Pharma Co., Ltd., Osaka, Japan
1 shared publicationChihiro Hasegawa
Clinical Pharmacology Development Area, MSD K.K., Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 71
Population pharmacokinetic analysis and exposure–response analysis of brexpiprazole in Japanese patients with agitation in Alzheimer's dementia
- 17 July 2026
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 71
Open AccessPopulation pharmacokinetic analysis and exposure–response analysis of brexpiprazole in Japanese patients with agitation in Alzheimer's dementia
- 11 February 2025
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 62, 101057
Population pharmacokinetics of brexpiprazole in Japanese healthy subjects and patients with schizophrenia
- 11 February 2025
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 62, 101057
Population pharmacokinetics of brexpiprazole in Japanese healthy subjects and patients with schizophrenia
- 6 January 2025
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 52 (1) , 1-18
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan
Model-informed drug development (MIDD) is an approach to improve the efficiency of drug development. To promote awareness and application of MIDD in Japan, the Data Science Expert Committee of the Drug Evaluation Committee in the Japan Pharmaceutical Manufacturers Association established a task force, which surveyed MIDD applications for approved products in Japan. This study aimed to reveal the trends and challenges in the use of MIDD by analyzing the survey results. A total of 322 cases approved in Japan between January 2020 and March 2022 as medical products were included in the survey. Modeling analysis was performed in approximately half of the cases (47.8% [154/322]) and formed a major basis for the selection or justification of dosage and administration in approximately one-fourth of the cases [24.2% (78/322)]. Modeling analysis/model-based dose selection was frequently conducted in cases involving monoclonal antibodies, first indication, orphan drugs, and multi-regional trials. Moreover, the survey results indicated that modeling analyses contributed to dose optimization throughout the developmental phases, including changing dose levels from phase II to phase III and dose adjustment in special populations. Japanese data were included in most cases in which modeling analysis was used for dosage selection. Thus, modelling analysis may also address ethnic factors introduced in the ICH E5 and/or E17 guidelines. In summary, this survey is useful for understanding the current status of MIDD use in Japan and for future drug development.
- 6 January 2025
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 52 (1) , 1-18
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan
Model-informed drug development (MIDD) is an approach to improve the efficiency of drug development. To promote awareness and application of MIDD in Japan, the Data Science Expert Committee of the Drug Evaluation Committee in the Japan Pharmaceutical Manufacturers Association established a task force, which surveyed MIDD applications for approved products in Japan. This study aimed to reveal the trends and challenges in the use of MIDD by analyzing the survey results. A total of 322 cases approved in Japan between January 2020 and March 2022 as medical products were included in the survey. Modeling analysis was performed in approximately half of the cases (47.8% [154/322]) and formed a major basis for the selection or justification of dosage and administration in approximately one-fourth of the cases [24.2% (78/322)]. Modeling analysis/model-based dose selection was frequently conducted in cases involving monoclonal antibodies, first indication, orphan drugs, and multi-regional trials. Moreover, the survey results indicated that modeling analyses contributed to dose optimization throughout the developmental phases, including changing dose levels from phase II to phase III and dose adjustment in special populations. Japanese data were included in most cases in which modeling analysis was used for dosage selection. Thus, modelling analysis may also address ethnic factors introduced in the ICH E5 and/or E17 guidelines. In summary, this survey is useful for understanding the current status of MIDD use in Japan and for future drug development.
- Open Access
- 30 October 2024
- Published by Springer Nature in Research Square
Population Pharmacokinetics of Brexpiprazole in Japanese Healthy Subjects and Patients with Schizophrenia
Brexpiprazole, widely approved for the treatment of schizophrenia, is an atypical antipsychotic that modulates serotonin–dopamine activity. To better understand the pharmacokinetics (PK) of brexpiprazole in Japanese patients, a population PK model was constructed and used to estimate steady state PK profiles and parameters as well as dopamine D2/D3 receptor occupancy profiles after repeated oral administrations of brexpiprazole at 1 and 2 mg/day. Nonlinear mixed effects modelling was used to analyse data from a total of 398 healthy subjects and patients with schizophrenia who received brexpiprazole in three Japanese clinical trials. The PK of brexpiprazole were well described by a two-compartment disposition model with transit absorption compartments. Estimated glomerular filtration rate, age and cytochrome P450 2D6 phenotype were identified as significant covariates on CL/F only. The model predicted that, at a dose of 2 mg/day, trough plasma concentration (90% prediction interval) of brexpiprazole is 77.1 (22.4–173) ng/mL and that dopamine D2/D3 receptor occupancy is > 80% over one day for most patients at steady state. This suggests the recommended maintenance dose of 2 mg/day of brexpiprazole leads to clinically useful dopamine D2/D3 receptor occupancy at steady state in Japanese patients.
- 30 October 2024
- Published by Springer Nature in Research Square
Open AccessPopulation Pharmacokinetics of Brexpiprazole in Japanese Healthy Subjects and Patients with Schizophrenia
Brexpiprazole, widely approved for the treatment of schizophrenia, is an atypical antipsychotic that modulates serotonin–dopamine activity. To better understand the pharmacokinetics (PK) of brexpiprazole in Japanese patients, a population PK model was constructed and used to estimate steady state PK profiles and parameters as well as dopamine D2/D3 receptor occupancy profiles after repeated oral administrations of brexpiprazole at 1 and 2 mg/day. Nonlinear mixed effects modelling was used to analyse data from a total of 398 healthy subjects and patients with schizophrenia who received brexpiprazole in three Japanese clinical trials. The PK of brexpiprazole were well described by a two-compartment disposition model with transit absorption compartments. Estimated glomerular filtration rate, age and cytochrome P450 2D6 phenotype were identified as significant covariates on CL/F only. The model predicted that, at a dose of 2 mg/day, trough plasma concentration (90% prediction interval) of brexpiprazole is 77.1 (22.4–173) ng/mL and that dopamine D2/D3 receptor occupancy is > 80% over one day for most patients at steady state. This suggests the recommended maintenance dose of 2 mg/day of brexpiprazole leads to clinically useful dopamine D2/D3 receptor occupancy at steady state in Japanese patients.
- Open Access
- 15 February 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (2) , e0160821
Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis
A population pharmacokinetic analysis of delamanid and its major metabolite DM-6705 was conducted to characterize the pharmacokinetics of delamanid and DM-6705 in pediatric participants with multidrug-resistant tuberculosis (MDR-TB). Data from participants between the ages of 0.67 and 17 years, enrolled in 2 clinical trials, were utilized for the analysis.
- 15 February 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (2) , e0160821
Open AccessPopulation Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis
A population pharmacokinetic analysis of delamanid and its major metabolite DM-6705 was conducted to characterize the pharmacokinetics of delamanid and DM-6705 in pediatric participants with multidrug-resistant tuberculosis (MDR-TB). Data from participants between the ages of 0.67 and 17 years, enrolled in 2 clinical trials, were utilized for the analysis.